Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Moderate Buy” by Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $19.30.

Several equities research analysts recently commented on YMAB shares. Brookline Capital Management assumed coverage on Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $17.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective for the company. Morgan Stanley cut their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research note on Wednesday. Finally, Truist Financial reduced their price target on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Paradigm Biocapital Advisors LP boosted its stake in Y-mAbs Therapeutics by 3.7% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock valued at $33,171,000 after purchasing an additional 150,000 shares during the last quarter. Acorn Capital Advisors LLC bought a new position in shares of Y-mAbs Therapeutics in the fourth quarter valued at approximately $22,408,000. Caligan Partners LP boosted its position in shares of Y-mAbs Therapeutics by 47.9% during the fourth quarter. Caligan Partners LP now owns 1,767,982 shares of the company’s stock valued at $13,843,000 after buying an additional 572,729 shares during the last quarter. State Street Corp grew its holdings in Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after buying an additional 405,169 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Y-mAbs Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 822,309 shares of the company’s stock valued at $6,440,000 after buying an additional 8,820 shares during the last quarter. 70.85% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ YMAB opened at $5.16 on Friday. The company’s 50 day moving average price is $6.34 and its 200-day moving average price is $10.54. Y-mAbs Therapeutics has a 52-week low of $4.25 and a 52-week high of $18.10. The company has a market capitalization of $231.11 million, a P/E ratio of -9.56 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $26.50 million during the quarter, compared to analyst estimates of $26.70 million. During the same quarter in the previous year, the firm earned ($0.02) EPS. Analysts forecast that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.